Sciogen

A novel quadrivalent influenza vaccine for active  prevention of disease caused by influenza virus infection. EC-QIV is a highly-immunogenic and cost-effective influenza vaccine with a novel manfacturing process specifically designed to overcome the shortfalls of current influenza vaccine products. The technology also provides significant surge capacity to quickly respond to changes in circulating influenza strains.      

A safe and effective monovalent pre-pandemic influenza vaccine. Pre-pandemic influenza vaccines are known to be poorly immunogenic in humans. Adjuvant, used to boost the immune responses, can cause diseases such as narcolepsy. EC-PIV is the result of an innovative design that improves vaccine effectiveness without the use of an adjuvant.

EC-RSV is a novel vaccine for the prevention of RSV infection, the leading cause of lower respiratory disease in infants. There is no vaccine available for the prevention of RSV. SG200 is based on the combination of a highly productive manufacturing technology and a novel vaccine design. In preclinical studies, SG200 provided complete protection against lower respiratory tract infection without inducing the inflammatory responses that were seen with previous unsuccessful RSV vaccines. 

A new class of highly effective-cross neutralizing monoclonal antibody for the treatment of severe influenza. Majority of influenza mAbs under development are cross-reactive but have low neutralizing activities. HC-imAb is designed to be both cross-reactive and highly neutralizing. It is intend to treat patients with life-threating influenza.  

Monoclonal antibody for the treatment of RSV infection. The product is designed to have optimized affinity and extended half-life in patients. It requires fewer injections and has the potential to be more effective than current available interventions.